Engagements like this almost always start the same way. A trial is already behind on enrollment, and medical affairs has never had a formal role on it: no established site relationships, no consolidated HCP or referrer contacts, nothing written down about who at a given site is genuinely engaged with the science and who has barely heard of the trial. Field medical is being deployed in a structured capacity for the first time, mid-crisis, into a picture nobody has actually mapped yet.
That absence of a starting point is often treated as an inconvenience to work around quickly, so the “real” work of diagnosis can begin. It’s worth treating it instead as part of the diagnostic job itself.
Start with what’s actually there
Before you can assess why a site is underperforming, you have to establish what already exists: informal relationships built from earlier, unrelated projects; scattered notes in a CRM nobody centralised; a referral contact a departed team member once cultivated and never logged anywhere retrievable. Assuming a blank slate when one doesn’t exist means duplicating work and missing context that’s already sitting somewhere in the organisation. Assuming context that isn’t there means building a diagnosis on relationships that never existed.
Phoenix Field Medical’s TRIAGE model treats this discovery as the first deliverable, not a delay. Every site’s first MSL touch is a baseline assessment: check what’s on file, map known HCPs and referrers, and complete an initial pass across the same six-domain framework used for every other site in the trial, flagging explicitly what was discovered versus what had to be built from nothing. Because every site starts from the same instrument, a finding from the first site visited and the fiftieth are directly comparable from day one, rather than being two different MSLs’ judgment calls, written up in two different formats, with two different implicit thresholds for what counts as a concern.
One site’s problem versus everyone’s problem
That consistency is what makes the underlying pattern visible, and this is where the real value compounds. A single site scoring poorly on referral awareness is a site-level fix: a KOL conversation, a targeted education visit, a conversation with the coordinator about screening workflow. The same score showing up across most of the sites in the trial is a different problem entirely: a protocol design issue, a comparator arm patients and physicians are quietly reluctant to accept, or a recent shift in standard of care that’s changed the equipoise argument. No amount of site-by-site field effort resolves a problem at that level. It needs to go back to the protocol or program team.
The difference between those two conclusions is the difference between a plan that actually works and one that quietly fails for another two quarters while everyone assumes it’s working. TRIAGE’s site-to-trial roll-up (a heat map of sites against domains) is built to surface which one you’re looking at within weeks of starting, not after a full enrollment cycle has already been spent finding out the hard way.
Consistency is the whole point
If you’re weighing whether a field medical deployment can genuinely recover the timeline on a trial that’s already lost time, the honest answer is that it depends almost entirely on whether the same instrument gets applied at every site from the outset. Applied inconsistently, you end up with the same scattered site notes you started with, just better formatted. Applied consistently, you get, for the first time, a real, evidence-backed picture of whether this is eighty sites with one shared problem or eighty different problems each needing a different answer. That picture is what tells you where to actually put whatever budget and time you have left.
Cost implications
| Metric | Tufts CSDD 2024 finding | Older industry range (Centre Watch, BCG) |
|---|---|---|
| Lost prescription sales per day of delay (median) | $500K to $800K1 | $600K to $8M2 |
| Phase III direct trial cost per day | $55,7161 | $35,0003,4 |
| Phase II direct trial costs per day | $23,7371 | n/a |
| Annual decline in average sales per day | $80K to $100K per year1 |
1 Tufts CSDD · 2 Boston Consulting Group · 3 DataEdge · 4 Applied Clinical Trials Online
Against numbers like these, the speed of an accurate diagnosis is the cost lever. Because TRIAGE applies the same six-domain instrument at every site from the first visit, it surfaces whether a trial faces one shared, trial-level problem or many separate site-level ones within weeks rather than after a full enrollment cycle, turning each day of delay it helps avoid directly into the lost prescription sales and direct trial costs shown above that are never incurred.
Local knowledge turns scores into accurate diagnosis
TRIAGE gives every assessment the same structure, but the people entering the scores still have to know what they’re looking at. Phoenix Field Medical’s consultants are experienced field medical professionals with deep therapeutic area backgrounds and, just as importantly, direct knowledge of the markets they work in: how referral patterns actually function in a given country, which regulatory quirks slow down site activation locally, and how a specific PI’s caution reads against the norms of that region rather than in the abstract.
That local grounding can change what a score means in practice. A KOL who seems hesitant might be raising a genuine concern in one market, or simply following a cautious professional norm that’s standard in that country and has nothing to do with the trial itself. A consultant who already understands the referral culture, the regulatory environment, and the professional relationships in a given region reads that correctly on the first visit, rather than needing several visits (and several missed weeks) to work it out. Someone new to the market, running through the same six domains without that context, can score the finding accurately on paper and still misjudge what it actually means for the trial.
That’s why Phoenix Field Medical pairs TRIAGE with consultants who already carry that regional knowledge, rather than treating the framework as something any available MSL can run without local context. A sponsor doesn’t just get a set of scores back: they get scores interpreted by someone who understood, before the first site visit even happened, what those scores were likely to mean in that market.
Phoenix Field Medical builds that baseline from day one of every TRIAGE deployment, even when medical affairs is walking into a trial with no prior footprint at all, and especially then. If that’s the position you’re in, we’d welcome the conversation.